About Daxor Corporation Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performanc ...

Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision ...

Core Insights - Daxor Corporation is expanding its ezBVA Lab service into three regional healthcare facilities across the U.S., enhancing blood volume analysis capabilities and improving patient outcomes while reducing costs [2][3] - The ezBVA Lab provides comprehensive blood volume analysis results within 24 hours for both inpatient and outpatient settings, showcasing the efficiency and effectiveness of Daxor's technology [2][3] - Daxor's BVA technology has been integrated into various healthcare settings, including a prominent Midwest academic medical center and a leading cardiovascular institute in New Jersey, indicating its growing significance in modern healthcare [3][6] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]